Clin Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Diabetes 25:135-140, 2007
DOI: 10.2337/diaclin.25.4.135
© 2007 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huizinga, M. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Huizinga, M. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Feature Article

Weight-Loss Pharmacotherapy: A Brief Review

Mary Margaret Huizinga, MD, MPH


   Abstract
Top
 Abstract
Introduction
 Weight-Loss Medications
 Appetite-Altering Drugs
 Absorption-Altering Drugs
 Thermogenesis-Increasing Drugs
 Agents on the Horizon
 Summary
 REFERENCES
 
IN BRIEF

The medical treatment of obesity is aimed at decreasing appetite, alterating absorption of calories, and increasing thermogenesis. Two agents are available for the long-term treatment of obesity: sibutramine, a centrally acting anorectic agent, and orlistat, which blocks the absorption of fat by inhibiting the enzyme lipase. Agents approved for short-term treatment include the central anorectic agents phentermine and diethylpropion. Other agents, including endocannabinoid system antagonists, anti-epileptic agents, and combination therapies, are under investigation.


   Introduction
Top
 Abstract
 Introduction
Weight-Loss Medications
 Appetite-Altering Drugs
 Absorption-Altering Drugs
 Thermogenesis-Increasing Drugs
 Agents on the Horizon
 Summary
 REFERENCES
 
The prevalence of obesity has significantly increased during the past 30 years. In 2004, > 30% of U.S. adults were classified as obese.1 Obesity is associated with many other chronic illnesses, including diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea.2 Modest weight loss of 5-10% has been shown to improve insulin sensitivity, improve glycemic control, and delay the onset of diabetes.3 However, weight loss is difficult for many patients to achieve. This article reviews current pharmacological options for weight loss and provides a brief synopsis of potential future options.

Weight regulation is a complex system of multiple overlying feedback systems. In the simplest terms, obesity results from greater energy intake than energy expenditure, although this balance is affected by genetics and environmental and cultural factors. Three primary mechanisms may be altered to reverse the state of greater energy intake than energy expenditure: food intake, nutrient handling, and energy expenditure (Figure 1). Many of the available and pending weight-loss medications address one of these three mechanisms; they either reduce appetite, decrease nutrient absorption, or increase thermogenesis.


Figure 1
View larger version (12K):
[in this window]
[in a new window]

  		Figure 1. Pharmacotherapy targets in obesity

 

Weight-loss medications are recommended, unless contraindicated, for patients who have a BMI ≥ 30 kg/m2 or > 27 kg/m2 with obesity-related comorbidities.4 Medications should be combined with nutrition education, behavioral intervention, an exercise program, and a long-term weight-maintenance plan. The addition of these lifestyle modifications to weight-loss pharmacology results in greater weight loss and treatment satisfaction.5 In general, weight-loss medications have a modest effect; this may be because of the complex regulatory system designed to prevent starvation.6


   Weight-Loss Medications
Top
 Abstract
 Introduction
 Weight-Loss Medications
Appetite-Altering Drugs
 Absorption-Altering Drugs
 Thermogenesis-Increasing Drugs
 Agents on the Horizon
 Summary
 REFERENCES
 
Weight-loss medications have had a tainted past. Among the first medications to be used for weight loss were thyroid hormone (1893) and digoxin (1940s), with disastrous results.7 The most infamous weight-loss medication is fenfluramine (part of the phentermine-fenfluramine combination known as "phen-fen"), which was pulled from the U.S. market in 1997 because of its association with valvular heart disease.8 However, many other weight-loss medications have also been pulled from the market. The first was dinitrophenol in 1934, because of an association with the development of cataracts and neuropathy.9 In addition to prescription medications, the U.S. Food and Drug Administration (FDA) has also removed common over-the-counter weight-loss medications from the market, including ephedra (ma-huang) because of its cardiovascular effects, and phenylpropanolamine, because it increased the risk of hemorrhagic stroke.10,11

There are other negative associations with weight-loss medications. In 1937, amphetamines were used to treat obesity and were associated with abuse.12 Since that time, medications with chemical structures similar to amphetamines have been avoided, regardless of whether abuse potential exists.

In addition to the often-negative view of weight-loss medications are their relative lack of efficacy. Most weight-loss medications result in a 5-10% weight loss.13 Many of these are approved for short-term use only, and when stopped, the weight is regained. However, many patients have obesity and obesity-related comorbidities that would be improved with modest weight loss. For some of these patients, the benefits of pharmacotherapy for weight loss may outweigh the risks.


   Appetite-Altering Drugs
Top
 Abstract
 Introduction
 Weight-Loss Medications
 Appetite-Altering Drugs
Absorption-Altering Drugs
 Thermogenesis-Increasing Drugs
 Agents on the Horizon
 Summary
 REFERENCES
 
Several categories of medications alter appetite, including the sympathomimetics, serotonergics, endocannaboid antagonists, and others. When discussing appetite, it is important to appreciate two distinct concepts of hunger. The first—satiety—refers to the sensation of feeling full when eating. A greater satiety means that a person hastens the cessation of eating. The second component of appetite is satiation, which is the length of time a person feels full after eating. Increased length of time between meals is referred to as increased satiation. If a drug reduces the time to satiety by half, but the patient eats twice as many meals, this will not lower total caloric intake. This concept is one of the reasons the phen-fen combination worked as well as it did. Phentermine is a sympathomimetic agent and increases the time between meals, whereas fenfluramine is a serotonergic agent that hastens the time to cessation of eating.14

All of the FDA-approved weight-loss medications that affect appetite are believed to act in the central nervous system to reduce caloric intake. However, there are other potential drug targets that may reduce appetite, including peripheral satiety and adipose signals.15

The centrally acting anorectics—sympathomimietic and serotonergic agents—were the first classes of medications to be approved for weight loss. As described above, both reduce caloric intake. All of the centrally acting anorectic agents except mazindol are derivatives of β-phenylethylamine similar to dopamine, norepinephrine, and epinephrine.16 Amphetamines have a similar chemical structure. These agents also have a wide range of effects. Some agents, such as phentermine, diethylpropion, and phendimetrazine, are similar to amphetamines and stimulate the release of norepinephrine, whereas other agents, such as dexfenfluramine and fenfluramine, affect serotonin release and reuptake.16,17 Sibutramine is in the middle of the spectrum and blocks the reuptake of norepinephrine, serotonin, and dopamine.18

In addition to the sympathomimietic and serotonergic agents, some anti-epileptic agents and antagonists to the endogenous endocannabinoid system (ECS) also reduce appetite. Topiramate is the most studied anti-epileptic agent in weight loss, although its exact mechanism of action is unknown.13 Another anti-epileptic agent, zonisamide, has also been found to have significant weight-loss effects.19 Zonisamide is believed to have dopaminergic and serotonergic activity, although its exact mechanism also remains unclear. No antagonist to the ECS has been approved by the FDA, although rimonabant is approved in the European Union. There have been concerns about the safety of rimonabant, namely increases in depressive and other psychiatric symptoms.20

Specific agents that reduce appetite
Phentermine was approved by the FDA in 1959 for short-term use in the treatment of obesity. In a recent meta-analysis, the expected weight loss greater than placebo was 3.6 kg (95% confidence interval [CI]: 0.6-6.0 kg).13 Possible side effects of phentermine include tachycardia, palpitations, elevated blood pressure, and gastrointestinal side effects. Phentermine is contraindicated in patients with recent acute myocardial infarction and uncontrolled hypertension.

Diethylpropion is similar in structure to bupropion, a drug used to treat depression and tobacco abuse. Like phentermine, diethylpropion is approved by the FDA for short-term treatment of obesity. The above-mentioned meta-analysis found that diethylpropion users lost an average of 3.0 kg (CI - 1.6 to 11.5 kg) greater than placebo.13 The side effects of diethylpropion are similar to those of amphetamines and include central nervous system stimulation, headache, insomnia, rash, and mild increases in heart rate and blood pressure.

Sibutramine is a newer agent and one of two drugs that is FDA-approved for long-term obesity treatment. The longest randomized controlled trial of sibutramine lasted 54 weeks. The recent meta-analysis found that sibutramine users lost an average of 4.5 kg (CI 3.6-5.3 kg) compared to placebo at 54 weeks.13 The most common adverse effects of sibutramine are headaches, constipation, insomnia, and nausea. In some patients, there is a risk for a substantial increase in blood pressure and heart rate. Patients should be monitored closely for increases in blood pressure and heart rate after initiation of sibutramine. Sibutramine is contraindicated for patients with uncontrolled hypertension, coronary artery disease, or other vascular disease.Go


View this table:
[in this window]
[in a new window]

  		Table 1. Weight-Loss Medications

 

Topiramate is FDA-approved for the treatment of seizures. Its exact mechanism of action is unknown. Topiramate has been noted to have a side effect of weight loss. Nine studies have assessed topiramate's weight-loss efficacy. The meta-analysis included six of these studies and found that patients on topiramate therapy lost an average 6.5 kg (CI 4.8-8.3 kg) more than those on placebo. Higher dosages are associated with greater weight loss. In addition, there is some evidence that topiramate may be efficacious in the treatment of binge eating disorder.21 The most common side effects of topiramate are fatigue, memory effects ("word searching"), parasthesias, and changes in taste. In addition, patients using topiramate are at risk for secondary acute angle glaucoma during the first month of therapy. Topiramate is also associated with decreases in serum bicarbonate and development of metabolic acidosis. Electrolytes should be monitored during topiramate therapy. However, topiramate is not FDA-approved for the treatment of obesity or binge eating disorder.

Zonisamide is another FDA-approved agent for the treatment of seizures. Zonisamide has dopaminergic and serotonergic activity.22 There is one published randomized controlled trial of zonisamide in weight loss.19 In that study, zonisamide use was associated with an average 5.0 kg (CI 0.62-9.4 kg) greater weight loss than placebo. The most common side effects of zonisamide are cognitive effects. There is also limited evidence that zonisamide may be efficacious in the treatment of binge eating disorder.23 Again, zonisamide is not FDA-approved for the treatment of obesity or binge eating disorder.


   Absorption-Altering Drugs
Top
 Abstract
 Introduction
 Weight-Loss Medications
 Appetite-Altering Drugs
 Absorption-Altering Drugs
Thermogenesis-Increasing Drugs
 Agents on the Horizon
 Summary
 REFERENCES
 
A parallel to decreasing caloric intake is to reduce the absorption of nutrients in the gastrointestinal system. The two most common drugs that alter absorption are orlistat and acarbose. Orlistat is a lipase inhibitor that reversibly inhibits human gastrointestinal lipases and is FDA-approved for the long-term treatment of obesity. Orlistat effectively blocks 30% of fat absorption.24 It is not absorbed and therefore does not have any systemic effects, although the gastrointestinal side effects may be substantial.25 Acarbose is FDA-approved for the treatment of type 2 diabetes and is an {alpha}-glucosidase inhibitor. Acarbose delays absorption of carbohydrate in the small intestine.26 It lowers postprandial glycemia, but it has little weight-loss effect and therefore is not an obesity treatment.27

Orlistat is the most studied weight-loss medication. In a recent meta-analysis that included 29 studies, orlistat was associated with an average increased weight loss of 2.9 kg (CI 2.3-3.5 kg) over placebo. The most common side effects are diarrhea, flatulence, bloating, abdominal pain, and dyspepsia. One study suggested that psyllium (6.0 g before bed) could reduce most of the unpleasant gastrointestinal side effects.28


   Thermogenesis-Increasing Drugs
Top
 Abstract
 Introduction
 Weight-Loss Medications
 Appetite-Altering Drugs
 Absorption-Altering Drugs
 Thermogenesis-Increasing Drugs
Agents on the Horizon
 Summary
 REFERENCES
 
No agent that specifically increases thermogenesis (basal metabolic rate) is available. However, several agents display thermogenic properties. The mechanism of weight loss with sibutramine is often proposed to be by both decreasing appetite and increasing energy expenditure through thermogenesis.29 A recent study found that the use of sibutramine increased thermogenesis after 12 weeks, whereas patients in the placebo arm had a decrease in thermogenesis.30 In addition, sibutramine has been shown to limit the decrease in resting energy expenditure often associated with weight loss.31,32

Some of the centrally acting anorectic agents also display thermogenic properties. Like sibutramine, mazindol is thermogenic in animal models.33-37 These two agents appear to have most thermogenetic properties of the centrally acting anorectics, but diethylpropion and fenfluramine also have thermogenic properties in animals.33,35 Thermogenesis is said to be present because there is stimulation of oxygen consumption or norepinephrine turnover. Unfortunately, the studies in humans are often contradictory, and therefore it is difficult to confirm the animal models of thermogenesis in humans.32,38-42

One of the most studied thermogenic agents is ephedrine (ephedra, or ma huang), which is no longer available on the U.S. over-the-counter market. Ephedrine causes weight loss by reducing appetite and increasing thermogenesis.43 Its mechanism of action is through both release of norepinephrine from the sympathetic nerve endings and as a direct agonist of β-receptors.44 The β-receptors are involved in the peripheral thermogenic effect.45 The thermogenic effects of ephedrine are synergistic with caffeine and aspirin.43,46 The use of these three medications became known as an "ECA stack."


   Agents on the Horizon
Top
 Abstract
 Introduction
 Weight-Loss Medications
 Appetite-Altering Drugs
 Absorption-Altering Drugs
 Thermogenesis-Increasing Drugs
 Agents on the Horizon
Summary
 REFERENCES
 
Several new agents are under investigation for weight loss. Some are drugs that are already FDA-approved for other indications; the manufacturers of many of these are seeking additional FDA-approved indications for weight loss. The U.S. Clinical Trials registration site (http://clinicaltrials.gov/ct/gui/action/GetStudy), when accessed on 12 July 2007, listed 291 studies in a search for "obesity treatment." These studies include diet, exercise, behavioral, and pharmacotherapy treatments. Our knowledge of obesity treatment will continue to grow as more studies are completed.

Incretin mimetics have been used in the treatment of diabetes and have weight-negative effects. They are now being investigated as weight-loss medications. Pramlintide is an amylin analog currently used in the treatment of diabetes in conjunction with insulin therapy. Amylin is secreted by pancreatic β-cells with insulin. It slows gastric emptying, promotes satiety, and inhibits glucagon.47 Pramlintide is now being investigated as a weight-loss agent in patients with non-insulin-requiring type 2 diabetes and obese patients without diabetes. In a recent Phase II study of obese patients with non-insulin-requiring type 2 diabetes, pramlintide use was associated with an average weight loss of 3.6 (± 0.6) kg greater than placebo.48 Initial studies performed in obese patients without type 2 diabetes have shown that 45% of patients treated with 360 µg of pramlintide twice a day maintained a 10% weight loss from initial body weight at 12 months compared to 13% of the placebo group.49

Another incretin mimetic, exenatide, is an analog of glucagon-like peptide 1 (GLP-1). GLP-1 is secreted by intestinal L-cells and is a potent stimulus of insulin secretion. In a meta-analysis, GLP-1 was found to acutely reduce food intake by 35%.50 However, GLP-1 has a very short half-life. Exenatide, derived from the saliva of Gila monsters, has a much longer half-life and is approved for the treatment of type 2 diabetes.51 After 24 months, exenatide was associated with a weight loss of 4.7 kg (standard error 0.3 kg) in an uncontrolled study of patients with type 2 diabetes.52 To date, no studies of exenatide as a weight-loss agent in obese patients without diabetes have been published.

Lorcaserin is a serontonergic (5HT2c agonist) drug in phase III trials as a weight-loss agent. Phase I and II trials were promising and did not reveal cardiac valvulopathy.15,53,54 Lorcaserin has high affinity for the 5HT2c receptor, which is active in appetite control, and low affinity for the 5HT2b receptor, the activation of which is believed to be associated with cardiac valvulopathy.55 Further studies are needed to determine this drug's safety and efficacy.

Several combination drugs are also currently under investigation. According to pharmaceutical company press releases, a combination of bupropion SR and naltrexone SR, known as Contrave, is in phase III trials56 A combination of bupropion and zonisamide, known as Empatic, is in phase II trials.57 A combination of phentermine and topiramate, known as Qnexa, is also in phase II trials.58 There has also been interest in the combination of agents such as pramlintide, peptide YY3-36, and leptin.59 Some believe that combination therapy is the most promising approach to overcome the body's multiple overlapping systems to prevent weight loss.60


   Summary
Top
 Abstract
 Introduction
 Weight-Loss Medications
 Appetite-Altering Drugs
 Absorption-Altering Drugs
 Thermogenesis-Increasing Drugs
 Agents on the Horizon
 Summary
REFERENCES
 
Obesity is a common disease with a substantial burden on both individuals and the U.S. health care system as a whole.61 The medical treatment of obesity has been confounded by worrisome adverse events and modest efficacy. However, many overweight and obese patients benefit from modest weight loss. Current guidelines recommend considering weight-loss pharmacotherapy for patients with a BMI ≥ 30 kg/m2 or > 27 kg/m2 with obesity-related comorbidities.

New understanding of weight regulation and the complex interplay of the multiple overlapping systems—including the neuroendocrine axis, gut satiety signals, peripheral adiposity indicators, and the genetic, environmental, and cultural factors that influence obesity—have provided additional insight into potential therapeutic targets. Evidence suggests that targeting one pathway alone is unlikely to result in sustained weight loss and that combination therapies are needed. Combination therapies may include the combination of medications or the combination of one medication with intensive lifestyle modification therapy.


   Footnotes
 
Mary Margaret Huizinga, MD, MPH, is an instructor in the Division of General Internal Medicine and Public Health, Department of Medicine, Center for Health Services Research, and assistant medical director at the Vanderbilt Center for Surgical Weight Loss at Vanderbilt University Medical Center in Nashville, Tenn.


   REFERENCES
Top
 Abstract
 Introduction
 Weight-Loss Medications
 Appetite-Altering Drugs
 Absorption-Altering Drugs
 Thermogenesis-Increasing Drugs
 Agents on the Horizon
 Summary
 REFERENCES
 
1 Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA295 : 1549-1555,2006[Abstract/Free Full Text]

2 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76 -79, 2003[Abstract/Free Full Text]

3 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393 -403, 2002[Abstract/Free Full Text]

4 National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res6 (Suppl. 2):51S -209S, 1998[Medline]

5 Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C: Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 161:218 -227, 2001[Abstract/Free Full Text]

6 Aronne LJ: Is rimonabant a safe and effective treatment for obesity? Nat Clin Pract Endocrinol Metab 3:388 -389, 2007[Medline]

7 Putnam JJ: Cases of myxedema and acromegalia treated with benefit by sheep's thyroids: recent observations respecting the pathology of the cachexias following disease of the thyroid; clinical relationships of grave's disease and acromegalia. Am J Med Sci 106:125 -148, 1893

8 Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-588,1997[Abstract/Free Full Text]

9 Masserman JH, Goldsmith H: Dinitrophenol: its therapeutic and toxic actions in certain types of psychobiologic underactivity. JAMA102 : 523-525,1934

10 Rados C: Ephedra ban: no shortage of reasons [article online]. FDA Consumer Magazine. Available from http://www.fda.gov/fdac/features/2004/204_ephedra.html. Accessed 12 July 2007

11 Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI: Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343:1826 -1832, 2000[Abstract/Free Full Text]

12 Lesses MF, Myerson A: Human autonomic pharmacology: XVI. Benzedrine sulfate as an aid in the treatment of obesity. N Engl J Med218 : 119-124,1938

13 Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC: Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532 -546, 2005[Abstract/Free Full Text]

14 Weintraub M, Hasday JD, Mushlin AI, Lockwood DH: A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 144:1143 -1148, 1984[Abstract]

15 Bays HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 12:1197 -1211, 2004[Medline]

16 Samanin R, Garattini S: Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol 73:63 -68, 1993[Medline]

17 Garattini S: Biological actions of drugs affecting serotonin and eating. Obes Res 3 (Suppl. 4):463S -470S, 1995[Medline]

18 Lean ME: How does sibutramine work? Int J Obes Relat Metab Disord25 (Suppl. 4):S8 -S11, 2001

19 Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA289 : 1820-1825,2003[Abstract/Free Full Text]

20 Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71 -77, 2007[Medline]

21 McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR: Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 61:1039 -1048, 2007[Medline]

22 Kawata Y, Okada M, Murakami T, Mizuno K, Wada K, Kondo T, Kaneko S: Effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus. Epilepsy Res35 : 173-182,1999[Medline]

23 McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D'Alessio DA, Keck PE, Hudson JI: Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry67 : 1897-1906,2006[Medline]

24 Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH: Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56:82 -85, 1994[Medline]

25 Heck AM, Yanovski JA, Calis KA: Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20:270 -279, 2000[Medline]

26 Zeymer U: Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. Int J Cardiol 107:11 -20, 2006[Medline]

27 Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH: Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord21 : 756-763,1997[Medline]

28 Cavaliere H, Floriano I, Medeiros-Neto G: Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord25 : 1095-1099,2001[Medline]

29 Nisoli E, Carruba MO: An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev1 : 127-139,2000[Medline]

30 Sarac F, Pehlivan M, Celebi G, Saygili F, Yilmaz C, Kabalak T: Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. Adv Ther 23:1016 -1029, 2006[Medline]

31 Walsh KM, Leen E, Lean ME: The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 23:1009 -1015, 1999[Medline]

32 Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A: Thermogenic effects of sibutramine in humans. Am J Clin Nutr 68:1180 -1186, 1998[Abstract]

33 Lang SS, Danforth E Jr, Lien EL: Anorectic drugs which stimulate thermogenesis. Life Sci 33:1269 -1275, 1983[Medline]

34 Yoshida T, Umekawa T, Wakabayashi Y, Yoshimoto K, Sakane N, Kondo M: Anti-obesity and anti-diabetic effects of mazindol in yellow KK mice: its activating effect on brown adipose tissue thermogenesis. Clin Exp Pharmacol Physiol 23:476 -482, 1996[Medline]

35 Lupien JR, Bray GA: Effect of mazindol, damphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue. Pharmacol Biochem Behav 25:733 -738, 1986[Medline]

36 Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ: Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol126 : 1487-1495,1999[Medline]

37 Giordano A, Centemeri C, Zingaretti MC, Cinti S: Sibutramine-dependent brown fat activation in rats: an immunohistochemical study. Int J Obes Relat Metab Disord 26:354 -360, 2002[Medline]

38 Breum L, Astrup A, Andersen T, Lammert O, Nielsen E, Garby L, Quaade F: The effect of longterm dexfenfluramine treatment on 24-hour energy expenditure in man: a double-blind placebo controlled study. Int J Obes14 : 613-621,1990[Medline]

39 Van Gaal LF, Vansant GA, Steijaert MC, De Leeuw IH: Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. Metabolism44 : 42-45,1995[Medline]

40 Scalfi L, D'Arrigo E, Carandente V, Coltorti A, Contaldo F: The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study. Int J Obes Relat Metab Disord 17: 91-96,1993[Medline]

41 Lafreniere F, Lambert J, Rasio E, Serri O: Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study. Int J Obes Relat Metab Disord 17: 25-30,1993[Medline]

42 Seagle HM, Bessesen DH, Hill JO: Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res6 : 115-121,1998[Medline]

43 Greenway FL: The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev2 : 199-211,2001[Medline]

44 Astrup A, Bulow J, Madsen J, Christensen NJ: Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol 248:E507 -E515, 1985[Medline]

45 Pasquali R, Cesari MP, Melchionda N, Stefanini C, Raitano A, Labo G: Does ephedrine promote weight loss in low-energy-adapted obese women? Int J Obes 11: 163-168,1987[Medline]

46 Astrup A, Breum L, Toubro S, Hein P, Quaade F: The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Relat Metab Disord 16:269 -277, 1992[Medline]

47 Schmitz O, Brock B, Rungby J: Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3): S233-S238, 2004[Abstract/Free Full Text]

48 Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C: Progressive reduction in body weight following treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92:2977 -2983, 2007[Abstract/Free Full Text]

49 Smith S, Klein E, Burns C, Kesty N, Halseth A, Weyer C: Sustained weight loss following 1-y pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes 56:A88 , 2007

50 Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A: A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382 -4389, 2001[Abstract/Free Full Text]

51 Giannoukakis N: Exenatide: Amylin/Eli Lilly. Curr Opin Investig Drugs4 : 459-465,2003[Medline]

52 Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther29 : 139-153,2007[Medline]

53 Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Thomsen WJ, Saldana HR, Whelan KT, Menzaghi F, Webb RR, Beeley NR: Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity. Bioorg Med Chem Lett 15:1467 -1470, 2005[Medline]

54 Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE: Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67:27 -55, 2007[Medline]

55 Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL: Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836 -2841, 2000[Abstract/Free Full Text]

56 Orexigen Therapeutics: Orexigen Therapeutics initiates Contrave phase III clinical trials [article online]. San Diego, Calif., Orexigen Therapeutics, 2007. Available from http://ir.orexigen.com/releasedetail.cfm?ReleaseID=244829. Accessed 12 July 2007

57 Orexigen Therapeutics: Orexigen Therapeutics reports positive phase II results for Empatic combination therapy to treat obesity [article online]. San Diego, Calif., Orexigen Therapeutics, 2006. Available from http://ir.orexigen.com/releasedetail.cfm?ReleaseID=224841. Accessed 12 July 2007

58 Nagarian T, Rowsemitt CN, Charbonneau V, Peterson CA: Evaluation of glycemic parameters in obese diabetic patients treated with phentermine and topiramate: outcomes in a private practice setting. Diabetes56 : A560,2007

59 Amylin Pharmaceuticals, Inc.: Amylin Pharmaceuticals expands clinical program in obesity [article online]. San Diego, Calif., Amylin Pharmaceuticals, 2006. Available from http://www.medicalnewstoday.com/medicalnews.php?newsid=54971. Accessed 12 July 2007

60 Korner J, Aronne LJ: Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab 89:2616 -2621, 2004[Free Full Text]

61 Wolf AM, Colditz GA: Current estimates of the economic cost of obesity in the United States. Obes Res 6:97 -106, 1998[Medline]


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huizinga, M. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Huizinga, M. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum